alexa Investigational antiretroviral drugs.
Bioinformatics & Systems Biology

Bioinformatics & Systems Biology

Journal of Proteomics & Bioinformatics

Author(s): Sen S, Mathur AG, Gupta RM, Kapila K, Chopra GS

Abstract Share this page

Abstract HIV disease is a chronic infection that requires lifelong treatment with the aim of suppressing the circulating viral load in order to improve the host immune status. The development of safe and effective antiretroviral agents with unique resistance profiles or novel mechanisms of action are an important goal for the long-term management of HIV-infected patients. The antiretroviral drug classes include entry and fusion inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and protease inhibitors. Current antiretroviral therapeutic regimens are associated with the emergence of issues like HIV drug resistance, drug toxicities, associated poor patient adherence to therapy, co-existence of other opportunistic, and blood borne viral infections. Newer antiretroviral agents may provide some alternatives to modulate the therapy as per the requirements of the HIV infected patients.
This article was published in Recent Pat Antiinfect Drug Discov and referenced in Journal of Proteomics & Bioinformatics

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 9th International Conference on Bioinformatics
    October 23-24, 2017 Paris, France
  • 9th International Conference and Expo on Proteomics
    October 23-25, 2017 Paris, France

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version